{"product_id":"map2k1-map2k2-antibody-sc-f0334","title":"MEK1\/2 Antibody","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003eMEK1\/2 is a target of interest in many antibody-based workflows. MEK1 and MEK2, are dual-specificity protein kinases also known as MAPK or Erk kinases, involved in a mitogen-activated protein kinase cascade regulating cell growth and differentiation. MEK1's structure, denoted for MAP kinase or ERK kinase, was elucidated from a complementary DNA sequence. Depending on the literature source, MEK1\/2 may also be discussed as MEK1\/2 and MAPKK 1.\u003c\/p\u003e\u003cp\u003eReported cellular context includes cytoplasm, cytoskeleton, membrane, and nucleus, which can matter when signal is compared across treatments or changing cell states. Following MEK1\/2 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state. In practice, this target is often considered at the family or isoform-group level, so experimental interpretation benefits from matched controls and clear comparison logic.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eMEK1\/2 is commonly interpreted in the context of cancer and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm, cytoskeleton, and membrane, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.\u003c\/p\u003e\u003cp\u003eConsider these angles when interpreting target-level changes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eapparent redistribution between cytoplasm, cytoskeleton, and membrane across matched conditions\u003c\/li\u003e\n\u003cli\u003echanges associated with proliferative state, oncogenic signaling, or treatment response\u003c\/li\u003e\n\u003cli\u003esignal-dependent shifts after ligand, inhibitor, or growth-factor perturbation\u003c\/li\u003e\n\u003cli\u003eco-patterning with orthogonal markers and control conditions that clarify pathway state\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVariant Considerations\u003c\/h2\u003e\u003cp\u003eIf your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for MEK1\/2. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.\u003c\/p\u003e\u003cp\u003eStandardize sampling time, control choice, and downstream analysis thresholds so apparent differences in MEK1\/2 reflect biology rather than handling. When interpreting MEK1\/2, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.\u003c\/p\u003e\u003cp\u003eFor multi-run studies, a shared reference condition can keep MEK1\/2 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"20 µl","offer_id":57577444180313,"sku":"F0334-20UL","price":139.0,"currency_code":"EUR","in_stock":true},{"title":"100 µl","offer_id":57577444213081,"sku":"F0334-100UL","price":329.0,"currency_code":"EUR","in_stock":true},{"title":"2 × 100 µl","offer_id":57577444245849,"sku":"F0334-2X100UL","price":489.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/F0334-IF.png?v=1773598353","url":"https:\/\/absource.de\/products\/map2k1-map2k2-antibody-sc-f0334","provider":"Absource Diagnostics","version":"1.0","type":"link"}